Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma.
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz J, Motoyama S et al, for the CheckMate 648 Trial Investigators.
N Engl J Med 2022; 386: 449-462.
A total of 970 patients with advanced oesophageal cancer were studied. The addition of nivolumab with, or without ipilimumab, to standard chemotherapy improved median survival: 13.2 months nivolumab with chemotherapy; 12.7 months with additional ipilimumab; 10.7 months chemotherapy alone. Survival was improved in tumours with PD-L1 expression of one percent or greater.
Comment: Some promise for a difficult disease.
1 March 2022Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.